These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21258822)

  • 21. Tapentadol: an initial analysis.
    Prommer EE
    J Opioid Manag; 2010; 6(3):223-6. PubMed ID: 20642251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tapentadol hydrochloride: a centrally acting oral analgesic.
    Wade WE; Spruill WJ
    Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the norepinephrine transporter (NET) inhibition on μ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model.
    Ono H; Nakamura A; Kanbara T; Minami K; Shinohara S; Sakaguchi G; Kanemasa T
    J Pharmacol Sci; 2014; 125(3):264-73. PubMed ID: 24965165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neurons.
    Sadeghi M; Tzschentke TM; Christie MJ
    Br J Pharmacol; 2015 Jan; 172(2):460-8. PubMed ID: 24372103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action.
    Caputi FF; Nicora M; Simeone R; Candeletti S; Romualdi P
    Minerva Med; 2019 Feb; 110(1):62-78. PubMed ID: 30667206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unique pharmacology of tapentadol for treating acute and chronic pain.
    Knezevic NN; Tverdohleb T; Knezevic I; Candido KD
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Tapentadol on Splenic Cytokine Production in Mice.
    Franchi S; Amodeo G; Gandolla M; Moschetti G; Panerai AE; Sacerdote P
    Anesth Analg; 2017 Mar; 124(3):986-995. PubMed ID: 27997452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tapentadol for pain: a treatment evaluation.
    Hartrick CT; Rodríguez Hernandez JR
    Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The noradrenergic component in tapentadol action counteracts μ-opioid receptor-mediated adverse effects on adult neurogenesis.
    Meneghini V; Cuccurazzu B; Bortolotto V; Ramazzotti V; Ubezio F; Tzschentke TM; Canonico PL; Grilli M
    Mol Pharmacol; 2014 May; 85(5):658-70. PubMed ID: 24516101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual μ-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain.
    Mao XF; Ahsan MZ; Apryani E; Tang XQ; Zhao MJ; Li XY; Wang YX
    Eur J Pharmacol; 2020 Jun; 876():173062. PubMed ID: 32173379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tapentadol and nitric oxide synthase systems.
    Bujalska-Zadrożny M; Wolińska R; Gąsińska E; Nagraba Ł
    Behav Pharmacol; 2015 Apr; 26(3):282-8. PubMed ID: 25485639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.
    Alshehri FS
    Drug Des Devel Ther; 2023; 17():851-861. PubMed ID: 36974332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considering tapentadol as a first-line analgesic: 14 questions.
    Pergolizzi JV; Breve F; Taylor R; Raffa RB; Strasburger SE; LeQuang JA
    Pain Manag; 2017 Jul; 7(4):331-339. PubMed ID: 28434283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is tapentadol an advance on tramadol?
    Guay DR
    Consult Pharm; 2009 Nov; 24(11):833-40. PubMed ID: 20092221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
    Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
    Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of tapentadol on neurons in the locus coeruleus.
    Torres-Sanchez S; Alba-Delgado C; Llorca-Torralba M; Mico JA; Berrocoso E
    Neuropharmacology; 2013 Sep; 72():250-8. PubMed ID: 23664814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic pain: the burden of disease and treatment innovations.
    Monti S; Caporali R
    Reumatismo; 2015 Oct; 67(2):35-44. PubMed ID: 26492961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tapentadol prolonged release in association with analgesic radiofrequency for the treatment of chronic lumbar radicular pain: an observational, prospective study.
    Visconti C; Mastroluca A; Varano L; Del Gaudio A
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):27-34. PubMed ID: 31755082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.